Enzo Biochem's Q1 Revenues Rise 2 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem today reported that its first-quarter 2011 revenues increased 2 percent as increased sales for its clinical labs business offset lower revenues for its life sciences unit.

The New York-based research products and testing firm brought in total revenues of $25.7 million for the three-month period ended Oct. 31, compared to revenues of $25.2 million for the first quarter of fiscal 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.